NCT00286325.

Trial name or title	Rituximab in the treatment of participants with bullous pemphigoid
Methods	Non‐randomised, open label, active control, single group assignment, safety/efficacy study
Participants	Bullous pemphigoid
Interventions	Infusion of 1000 mg of rituximab on day 0 and day 14
Outcomes	To determine the safety of rituximab for treatment of participants with bullous pemphigoid (time frame: 1 year) (designated as safety issue: yes)
Starting date	March 2005
Contact information	Russell Hall, III, MD Duke University Medical Center Durham, North Carolina 27710 United States
Notes	‐